TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Jan 19, 2023 10:35 JST
Source:
Eisai
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel
TOKYO, Jan 19, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Israel Ltd., a pharmaceutical sales subsidiary recently established in Tel Aviv in the State of Israel (Israel). Eisai Israel is a wholly-owned subsidiary of Eisai's European regional headquarters, Eisai Europe Ltd.
Israel's pharmaceutical market reached 5.3 billion USD in 2021.1 The compound annual growth rate of the Israel pharmaceutical market from 2018 to 2021 was +8.56%1 and the market is expected to continue to grow steadily, with a high penetration rate of innovative medicines.
In 2011, Eisai Europe started business in Israel marketing and selling Eisai products through local distribution partners, and mainly marketed Lenvima, Halaven, Fycompa and Inovelon. Eisai Israel was established in August 2021, and in January 2023, became the marketing authorization holder of the Eisai products in Israel. Eisai Israel will now perform sales and marketing activities for these products. The company plans to launch its other global brands in the future.
With the commencement of operations at Eisai Israel, Eisai aims to utilize its own drug sales system in Israel, deliver innovative new drugs to more patients in Israel as quickly as possible, and contribute to improving the benefits of patients and their families.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
January 13 2026 08:50 JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
January 06 2026 09:43 JST
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
December 11 2025 18:41 JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
December 09 2025 17:51 JST
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
December 04 2025 17:36 JST
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 03 2025 17:19 JST
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
December 02 2025 23:01 JST
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
November 28 2025 22:00 JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
November 26 2025 18:42 JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
November 17 2025 21:08 JST
More Press release >>
Latest Press Release
DENSO to Promote Standardization of Automotive Software as an AUTOSAR Core Partner
Jan 19, 2026 16:00 JST
New-look TGR-WRT launches landmark campaign on legendary rally
Jan 16, 2026 21:34 JST
Mitsubishi Corporation Announces Acquisition of Haynesville Shale Gas Business in Louisiana and Texas
Jan 16, 2026 21:12 JST
MHI Thermal Systems Expands Lineup of Building-Use Multi-Split Air-Conditioners for Overseas Markets
Jan 16, 2026 15:47 JST
NEC Launches "NEC Composable Disaggregated Infrastructure Solution" for Distributed Computing Resources
Jan 15, 2026 17:00 JST
Mitsubishi Power Lands Significant Gas Turbine Order for Qatar's Facility E IWPP Project
Jan 14, 2026 18:58 JST
Mitsubishi Motors Launches Updated Outlander PHEV in Canada
Jan 14, 2026 17:38 JST
Hitachi High-Tech launches FOUNDRY-MASTER Smart 2, enhancing performance and value of stationary optical emission spectrometers
Jan 14, 2026 14:10 JST
Fujitsu launches demonstration experiment into green steel value flow utilizing blockchain technology to accelerate decarbonization in the steel Industry
Jan 14, 2026 10:52 JST
Toyota Systems, Fujitsu utilize quantum-inspired technology and AI to streamline on-board computer design and contribute to sustainable development
Jan 14, 2026 10:36 JST
Mitsubishi Motors Starts Production of Rogue Plug-in Hybrid and Navara OEM Models for Nissan
Jan 13, 2026 16:02 JST
Additional Investment in Commercial Space Station Business and Acquisition of Experimental Module Usage Rights
Jan 13, 2026 14:34 JST
Honda to Adopt New "H mark" as Symbol of Honda Automobile Business
Jan 13, 2026 11:26 JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
Jan 13, 2026 09:50 JST
Mazda Unveils MAZDA CX-6e New Battery EV in World Premiere
Jan 12, 2026 13:10 JST
TOYOTA GAZOO Racing Announces GR Yaris MORIZO RR
Jan 09, 2026 16:03 JST
Honda Announces New Lines of Models that Represent "Honda Sports DNA" at Tokyo Auto Salon 2026
Jan 09, 2026 14:24 JST
Honda Launches Fixed-Battery Electric Two-Wheeled Personal Commuter "Honda UC3" in Thailand and Vietnam
Jan 09, 2026 13:27 JST
Sponsorship Agreement Reached with LCR Honda; Full-Season MotoGP Entry as Pro Honda LCR
Jan 09, 2026 13:05 JST
Mazda Develops New Body Color, "Navy Blue Mica"
Jan 09, 2026 10:23 JST
More Latest Release >>